Support for recommending minimum CD4 and CD8 values for live vaccine administration was highlighted in a 2007 publication involving a case report of a 13-month male with a hemizygous 22q11.2 deletion, who at 8 months of age was found to have significant T cell lymphopenia, with CD3+ 396 cells/μl (21%) (normal 2400–6900 (50–77%)): CD4+ 320 cells/μl (17%) (normal 1400–5100 (33–58%)), and CD8+ 57 cells/μl (normal 600–2200 (13–26%)) [116]. The gene discussed is CD8A; the disease is lymphopenia.